Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01178073 · ClinicalTrials.gov registry record · Phase 3
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 610
- Enrollment target
NCT01178073 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 610 participants.
The verdict
NCT01178073, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 610 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in subjects with Pulmonary Arterial Hypertension. This will be assessed by time to the first clinical failure event.
Interventions
- DRUG tadalafil
- DRUG ambrisentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 610 participants |
| Start Date | 2010-10-01 |
| Est. Completion | 2014-07-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01178073
The ClinicalTrials.gov registry entry for NCT01178073 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 610 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which tadalafil is the first listed.
NCT01178073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01178073 about?
NCT01178073 is a clinical study titled "A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)". The purpose of this study is to compare the two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in subjects with Pulmonary Arterial Hypertension. This will be assessed by time to the first clinical failure even...
What is the current status of trial NCT01178073?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 610 participants. The study started on 2010-10-01. Estimated completion is 2014-07-31.
What interventions are being tested in trial NCT01178073?
The interventions under investigation include: tadalafil (DRUG), ambrisentan (DRUG).
Who is sponsoring clinical trial NCT01178073?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.